ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2015
Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 143 citations in OpenAlex.
- PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.European journal of nuclear medicine and molecular imaging · 2023Guideline
- 68Ga-Prostate-specific membrane antigen (psma) positron emission tomography (pet) in prostate cancer: a systematic review and meta-analysis.International braz j urol : official journal of the Brazilian Society of UrologyPooled it
- AnCurrent radiopharmaceuticals · 2024Trial
- Diagnostic Performance ofClinical cancer research : an official journal of the American Association for Cancer Research · 2021Trial
- Efficacy, safety, and quality of life outcomes of [International urology and nephrology · 2026Review
- Review
- Fluorescent PSMA-Targeted Radiotheranostic Compounds for Multiscale Imaging.Bioconjugate chemistry · 2025Article
- Exploring the Therapeutic Potential ofInternational journal of molecular sciences · 2025Article
- Article
- Development of a CT-less SPECT Acquisition Protocol for Kidney Dosimetry inMolecular imaging and biology · 2025Article
- Review
- Review
- Improved Accuracy and Reliability of PRIMARY Scoring Using Delayed [Molecular imaging and radionuclide therapy · 2025Article
- Scalability study on [EJNMMI radiopharmacy and chemistry · 2024Article
- Lessons learned in application driven imaging agent design for image-guided surgery.European journal of nuclear medicine and molecular imaging · 2024Review
- Up-Regulation of PSMA Expression In Vitro as Potential Application in Prostate Cancer Therapy.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Head-to-head comparison of [European journal of nuclear medicine and molecular imaging · 2022Article
- Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled withJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors?EJNMMI radiopharmacy and chemistry · 2021Article
- Validation of HPLC method for the determination of chemical andradiochemical purity of aTurkish journal of chemistry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 2 countries.
Funding
Abstract
unlabelledProstate-specific membrane antigen (PSMA) is a promising target for diagnosis and treatment of prostate cancer. EuK-Subkff-(68)Ga-DOTAGA ((68)Ga-PSMA Imaging & Therapy [PSMA I&T]) is a recently introduced PET tracer for imaging PSMA expression in vivo. Whole-body distribution and radiation dosimetry of this new probe were evaluated.
methodsFive patients with a history of prostate cancer were injected intravenously with 91-148 MBq of (68)Ga-PSMA I&T (mean ± SD, 128 ± 23 MBq). After an initial series of rapid whole-body scans, 3 static whole-body scans were acquired at 1, 2, and 4 h after tracer injection. Time-dependent changes of the injected activity per organ were determined. Mean organ-absorbed doses and effective doses were calculated using OLINDA/EXM.
resultsInjection of 150 MBq of (68)Ga-PSMA I&T resulted in an effective dose of 3.0 mSv. The kidneys were the critical organ (33 mGy), followed by the urinary bladder wall and spleen (10 mGy each), salivary glands (9 mGy each), and liver (7 mGy).
conclusion(68)Ga-PSMA I&T exhibits a favorable dosimetry, delivering organ doses that are comparable to (kidneys) or lower than those delivered by (18)F-FDG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.